Clinical Trial: NCT04685135
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Mirati Therapeutics Inc. |
| Information Provided By: | Mirati Therapeutics Inc. |
| Last Update Posted: | 2026-08-11 |
Study Overview
Brief Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Official Title
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Conditions
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: MRTX849
- Drug: Docetaxel
Other Study ID Numbers
- CA239-0013
- CA239-0013
- 849-012
Start Date (Actual)
2021-02-23
Primary Completion Date (Actual)
2023-12-30
Study Completion Date (Estimated)
2026-10-30
Enrollment (Actual)
453
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Mirati Therapeutics Inc. |
| Information Provided By: | Mirati Therapeutics Inc. |
| Last Update Posted: | 2026-08-11 |
Study Overview
Brief Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Official Title
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Conditions
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: MRTX849
- Drug: Docetaxel
Other Study ID Numbers
- CA239-0013
- CA239-0013
- 849-012
Start Date (Actual)
2021-02-23
Primary Completion Date (Actual)
2023-12-30
Study Completion Date (Estimated)
2026-10-30
Enrollment (Actual)
453
Study Type
Interventional
Phase
Phase 3